rs121434569
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
While they produce dramatic responses in a subset of patients-primarily those with activating EGFR mutations-remissions are typically limited to several months due to acquired drug resistance, frequently associated with the secondary T790M mutation in EGFR.In this issue of Cancer Cell, Li et al. report that an irreversible EGFR kinase inhibitor, HKI-272, had limited activity in a mouse lung cancer model driven by an EGFR mutant harboring T790M and an activating mutation.
|
17613432 |
2007 |
rs121434569
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Importantly, we observed that the combination of PI3K-mTOR and MEK inhibitors effectively shrunk tumors in a transgenic and xenograft model of EGFR T790M-L858R cancers.
|
19850869 |
2009 |
rs121434568
|
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
Importantly, we observed that the combination of PI3K-mTOR and MEK inhibitors effectively shrunk tumors in a transgenic and xenograft model of EGFR T790M-L858R cancers.
|
19850869 |
2009 |
rs1057519848
|
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
Importantly, we observed that the combination of PI3K-mTOR and MEK inhibitors effectively shrunk tumors in a transgenic and xenograft model of EGFR T790M-L858R cancers.
|
19850869 |
2009 |
rs1057519847
|
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
Importantly, we observed that the combination of PI3K-mTOR and MEK inhibitors effectively shrunk tumors in a transgenic and xenograft model of EGFR T790M-L858R cancers.
|
19850869 |
2009 |
rs121434569
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The molecular beacon-based approach enabled rapid and sensitive detection of the EGFR mutation (T790M) in NSCLC with in situ fluorescence imaging, which can be directed to determine various treatment options in patients with cancer.
|
20805561 |
2010 |
rs121434569
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, a vast majority of the patients experience recurrence of the cancers by a secondary mutation of EGFR (T790M).
|
21635547 |
2011 |
rs397517132
|
|
Malignant Neoplasms
|
|
0.090 |
GeneticVariation
|
BEFREE |
The aim of the correlative tumour tissue studies was to investigate the relationship between EGFR gene copy numbers, activation of the EGFR pathway, expression and mutation of E-cadherin, V600E BRAF mutation and clinical outcome of patients with gastric and OGJ cancer treated with cetuximab combined with FUFOX.
|
22152101 |
2011 |
rs397517132
|
|
Malignant Neoplasms
|
|
0.090 |
GeneticVariation
|
BEFREE |
The BRAF inhibitor vemurafenib has become an important treatment option for melanoma patients, the majority of whom have a BRAF(V600E) mutation driving their malignancy.
|
23074264 |
2012 |
rs121434568
|
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
The results of cancer tissue specimens were identical to those with existing systems (nucleic acid-locked nucleic acid PCR clamp or cycleave PCR), except for two samples that showed both exon 19 deletions and L858R.
|
22858585 |
2012 |
rs1057519848
|
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
The results of cancer tissue specimens were identical to those with existing systems (nucleic acid-locked nucleic acid PCR clamp or cycleave PCR), except for two samples that showed both exon 19 deletions and L858R.
|
22858585 |
2012 |
rs1057519847
|
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
The results of cancer tissue specimens were identical to those with existing systems (nucleic acid-locked nucleic acid PCR clamp or cycleave PCR), except for two samples that showed both exon 19 deletions and L858R.
|
22858585 |
2012 |
rs987532315
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
In exon 20, a variant from CAG to CAA at codon 787 (2361G-> A) was identified in 19 patients, which was a genomic variation of EGFR since it was found in both cancer tissue and white blood cells.
|
22252115 |
2012 |
rs1050171
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
In exon 20, a variant from CAG to CAA at codon 787 (2361G-> A) was identified in 19 patients, which was a genomic variation of EGFR since it was found in both cancer tissue and white blood cells.
|
22252115 |
2012 |
rs397517132
|
|
Malignant Neoplasms
|
|
0.090 |
GeneticVariation
|
BEFREE |
The usefulness of immunohistochemistry (IHC) as a new approach for the detection of BRAF V600E in cancer patients has been recently reported.
|
23927882 |
2013 |
rs121913444
|
|
Malignant Neoplasms
|
|
0.020 |
GeneticVariation
|
BEFREE |
Our studies identify T725M and L861R as rare cancer-associated mutations inasmuch as these mutations increase EGFR activity in the absence of the activating EGF ligand in cell-based assays.
|
24743239 |
2014 |
rs767505234
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Our studies identify T725M and L861R as rare cancer-associated mutations inasmuch as these mutations increase EGFR activity in the absence of the activating EGF ligand in cell-based assays.
|
24743239 |
2014 |
rs121434569
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.
|
25934077 |
2015 |
rs121434568
|
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
The purpose of this study was to clarify the relationship between the EGFR-L858R mutation and cancer cell invasion ability and to investigate the molecular mechanisms involved in the formation of MPE.
|
26338423 |
2015 |
rs1057519848
|
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
The purpose of this study was to clarify the relationship between the EGFR-L858R mutation and cancer cell invasion ability and to investigate the molecular mechanisms involved in the formation of MPE.
|
26338423 |
2015 |
rs1057519847
|
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
The purpose of this study was to clarify the relationship between the EGFR-L858R mutation and cancer cell invasion ability and to investigate the molecular mechanisms involved in the formation of MPE.
|
26338423 |
2015 |
rs121434569
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The objective responses were observed in NSCLC patients with EGFR T790M mutation.Mol Cancer Ther; 15(11); 2586-97.©2016 AACR.
|
27573423 |
2016 |
rs121434569
|
|
Malignant Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
In two patients, the ctDNA dynamics suggested the presence of cancer cell populations only with the T790M mutation.
|
26678713 |
2016 |
rs397517132
|
|
Malignant Neoplasms
|
|
0.090 |
GeneticVariation
|
BEFREE |
We found that gene mutations for EGFR (P = .02) and ALK (P < .001) were associated with cancer diagnosis at a younger age, and a similar trend existed for ERBB2 (P = .15) and ROS1 (P = .10) but not BRAF V600E (P = .43).
|
26720421 |
2016 |
rs961150162
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
The DDR2 E655K mutation can play a role in cancer progression by reducing the growth-inhibitory effect of collagen.Clin Cancer Res; 22(14); 3663-71.©2016 AACR.
|
26826182 |
2016 |